GoodRx stock soars after CEO hints at potential TrumpRx partnership
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Morgan Stanley Reiterates Equalweight Rating on GoodRx Holdings Inc. (GDRX) Amid Speculation of TrumpRx
October 2, 2025 4:33 AM EDTMorgan Stanley analyst Craig Hettenbach reiterated an Equalweight rating and $5.00 price target on GoodRx Holdings Inc. (NASDAQ: GDRX)
The analyst comments "GDRX traded materially higher today (+19% vs. Russell 2000 +0.2%) on heavy volume (22mn shares or ~10x daily average) following news that the company could potentially partner with TrumpRx. This was discussed during an interview CEO Wendy Barnes had on Fox Business (article). Separately, we view news of an expansion with Kroger (covered by Simeon Gutman) as potentially the more meaningful... More
